ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

P. A. Ascierto; P. Arenberger; V. G. Atkinson; J. Hansson; E. Kapiteijn; C. Loquai; S. Negrier; H. M. Shaw; A. Tarhini; J. Walker; J. Geib; S. Rahimian; S. Swann; A. Diab

doi:10.1093/annonc/mdy289.062

ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

P. A. Ascierto, P. Arenberger, V. G. Atkinson, J. Hansson, E. Kapiteijn, C. Loquai, S. Negrier, H. M. Shaw, A. Tarhini, J. Walker, J. Geib, S. Rahimian, S. Swann, A. Diab

Melanoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii466
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.062
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy289.062

Cite this

Ascierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S., & Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii466. https://doi.org/10.1093/annonc/mdy289.062

ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. / Ascierto, P. A.; Arenberger, P.; Atkinson, V. G. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii466.

Research output: Contribution to journal › Article › peer-review

Ascierto, PA, Arenberger, P, Atkinson, VG, Hansson, J, Kapiteijn, E, Loquai, C, Negrier, S, Shaw, HM, Tarhini, A, Walker, J, Geib, J, Rahimian, S, Swann, S & Diab, A 2018, 'ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii466. https://doi.org/10.1093/annonc/mdy289.062

@article{a422627369f44a25b129d8a44e442840,

title = "ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma",

author = "Ascierto, {P. A.} and P. Arenberger and Atkinson, {V. G.} and J. Hansson and E. Kapiteijn and C. Loquai and S. Negrier and Shaw, {H. M.} and A. Tarhini and J. Walker and J. Geib and S. Rahimian and S. Swann and A. Diab",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.062",

language = "English (US)",

volume = "29",

pages = "viii466",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - ILLUMINATE 301

T2 - A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

AU - Ascierto, P. A.

AU - Arenberger, P.

AU - Atkinson, V. G.

AU - Hansson, J.

AU - Kapiteijn, E.

AU - Loquai, C.

AU - Negrier, S.

AU - Shaw, H. M.

AU - Tarhini, A.

AU - Walker, J.

AU - Geib, J.

AU - Rahimian, S.

AU - Swann, S.

AU - Diab, A.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081529408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081529408&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy289.062

DO - 10.1093/annonc/mdy289.062

M3 - Article

C2 - 32137196

SN - 0923-7534

VL - 29

SP - viii466

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this